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ESTIMATION OF AREA UNDER THE ROC CURVE
UNDER NONIGNORABLE VERIFICATION BIAS
Wenbao Yu, Jae Kwang Kim and Taesung Park
Children’s Hospital of Philadelphia, Iowa State University and
Seoul National University
Abstract: The Area Under the Receiving Operating Characteristic Curve (AUC) is
frequently used for assessing the overall accuracy of a diagnostic marker. However,
estimation of AUC relies on knowledge of the true outcomes of subjects: diseased
or non-diseased. Because disease verification based on a gold standard is often ex-
pensive and/or invasive, only a limited number of patients are sent to verification
at doctors’ discretion. Estimation of AUC is generally biased if only small verified
samples are used and it is thus necessary to make corrections for such lack of in-
formation. Correction based on the ignorable missingness assumption (or missing
at random) is also biased if the missing mechanism depends on the unknown dis-
ease outcome, which is called nonignorable missing. In this paper, we propose a
propensity-score-adjustment method for estimating the AUC based on the instru-
mental variable assumption when the missingness of disease status is nonignorable.
The new method makes parametric assumptions on the verification probability,
and the probability of being diseased for verified samples rather than for the whole
sample. The proposed parametric assumption on the observed sample is easier to
be verified than the parametric assumption on the full sample. We establish the
asymptotic properties of the proposed estimators. A simulation study was per-
formed to compare the proposed method with existing methods. The proposed
method is applied to an Alzheimer’s disease data collected by National Alzheimer’s
Coordinating Center.
Key words and phrases: Instrumental variable, missing data, not missing at ran-
dom, ROC curve.
1. Introduction
The Receiving Operating Characteristic (ROC) curve is a tool for evaluating
the accuracy of a diagnostic marker. The area under the curve (AUC) is a pop-
ular summary index for evaluating a method’s power of discriminating diseased
from non-diseased subjects; it is the probability that the score of a randomly
chosen diseased individual exceeds that of a randomly chosen non-diseased sub-
jects (Bamber (1975)). Estimation of the AUC relies on knowledge of the true
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status of subjects, which can usually be verified through a gold standard, but
it is expensive, invasive or both. On the other hand, the estimation based on
verified sub-samples only is generally biased (Begg and Greenes (1983)).
A common assumption in adjusting verification bias is that the verification
mechanism is ignorable, also known as missing at random (MAR): the selection of
a subject for verification is independent of the subject’s disease status, conditional
on the score of the marker and other covariates. Approaches based on the MAR
assumption have been proposed by, for example, Begg and Greenes (1983), Zhou
(1996, 1998), Rodenberg and Zhou (2000), Alonzo and Pepe (2005), He, Lyness
and McDermott (2009) and He and McDermott (2011). See Zhou, Obuchowski
and McClish (2011) for a comprehensive overview of these works.
The MAR assumption can be unrealistic when the doctors’ decision to send
a subject to verification is based on his or her detailed information on that sub-
ject, which may depend on some un-measured covariates related to disease status
(Rotnitzky, Faraggi and Schisterman (2006)); such is known as nonignorable ver-
ification bias. The earlier existing works under nonignorable verification bias are
limited to dichotomous or ordinal markers, including Baker (1995), Zhou and
Rodenberg (1998), Kosinski and Barnhart (2003), Zhou and Castelluccio (2003)
and Zhou and Castelluccio (2004). Two methods proposed by Rotnitzky, Faraggi
and Schisterman (2006) and Liu and Zhou (2010) under nonignorable verification
bias can efficiently estimate AUC for markers that are measured in continuous,
ordinal or dichotomous scales. In particular, Rotnitzky, Faraggi and Schisterman
(2006) proposed a doubly robust estimator of AUC, with the validity of the esti-
mator only requiring either the disease model (the probability of being diseased
given covariates) or the verification model (the probability of being verified given
some covariates and the true disease outcome) to be correctly specified. The
nonignorabilty parameter (the coefficient of the disease outcome) in their verifi-
cation model was not identifiable, and thus a sensitivity analysis was suggested.
Liu and Zhou (2010) suggested a parametric model to estimate the nonignor-
ability parameter; they assumed a parametric disease regression model of the
responses for the whole sample and jointly estimated the verification probability
and the disease probability. Such a parametric assumption is hard to be verified
in practice.
In this paper, we consider estimating the nonignorability parameter based
on maximum likelihood method under an identifiability assumption based on an
instrumental variable (Wang, Shao and Kim (2014)). We use a similar idea as
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the propensity-score-adjustment method proposed by Sverchkov (2008) and Rid-
dles, Kim and Im (2016), developed in the context of survey sampling, to correct
nonignorable verification bias in AUC estimators. It is based on a parametric
assumption of the disease model for observed subjects, and a parametric assump-
tion of the verification model. An instrumental variable can be used to construct
a reduced verification model and results in efficient estimation.
The rest of this paper is organized as follows. In Section 2, we present
our proposed estimator. Its asymptotic properties are discussed in Section 3.
Simulation studies and real data analysis are provided in Section 4. We end our
paper with a brief discussion in Section 5.
2. Methods
2.1. Basic setup
Consider a sample of size n, assumed to be a random sample. Suppose
Yi = 1 if the sample i is from diseased group, and Yi = 0 otherwise, and Xi and
V i are the marker of interest and the covariates, respectively. Let Ri = 1 if Yi
is observed and Ri = 0 otherwise, i = 1, . . . , n. Based on the result of Bamber
(1975), the AUC of marker X is
AUC =
E{Y1(1− Y2)I12}
E{Y1(1− Y2)} , (2.1)
where I12 = I(X1 > X2) + 0.5I(X1 = X2) and I(·) is the indicator function. If
there is no missing value, AUC can be estimated by
Aˆ =
∑n
i=1
∑
j 6=i Yi(1− Yj)Iij∑n
i=1
∑
j 6=i Yi(1− Yj)
, (2.2)
where Iij = I(Xi > Xj) + 0.5I(Xi = Xj).
2.2. Estimator of AUC with adjustment of verification bias
Since some Y s in (2.2) are unobserved, we need to model the distribution of
the disease status Y based on the information of X and covariates V . Assume
that the covariates can be decomposed into V = (V 1,V 2) and the dimension of V 2
is greater than or equal to one. We assume that V 2 is conditionally independent
of R given (X,Y,V 1). The variable V 2 is called a (nonresponse or) instrument
variable (IV) and it helps to make the model identifiable (Wang, Shao and Kim
(2014)). We then define the verification model as
pii = pr(Ri = 1|Xi,V i, Yi) = pi(Xi,V 1i, Yi;φ), (2.3)
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where pi(·) is a known function and φ is the unknown parameter. The IV assump-
tion (2.3) is a way of making a reduced model for pii. Roughly speaking, IV can
reduce the number of parameters to be estimated and ensure the identifiability
of the reduced model. In practice, the IV assumption is hard to be verified, but
as confirmed in the simulation study in Section 4, the proposed method shows
reasonable performance even when the IV assumption is weakly violated.
We write φ = (ψ1, ψ2,ψ3, β) and assume
pi(Xi,V 1i, Yi;φ) =
1
1 + exp(ψ1 + ψ2Xi +ψ3V 1i + βYi)
, (2.4)
a logistic regression model using (X,V 1, Y ) as explanatory variables. Parameter
β is the nonignorability parameter; if β = 0, then the response mechanism is
MAR. We have
E{R1pi−11 R2pi−12 Y1(1− Y2)I12}
E{R1pi−11 R2pi−12 Y1(1− Y2)}
=
E{Y1(1− Y2)I12}
E{Y1(1− Y2)} . (2.5)
Thus, if a consistent estimator pˆii of pii is available, we can estimate AUC by
an inverse weighted type of estimator,
Aˆiv =
∑n
i=1
∑
j 6=iRipˆi
−1
i Rj pˆi
−1
j Yi(1− Yj)Iij∑n
i=1
∑
j 6=iRipˆi
−1
i Rj pˆi
−1
j Yi(1− Yj)
. (2.6)
We estimate pii, or equivalently, to estimate φ in the verification model (2.3).
2.3. Parameter estimation
To estimate φ in the verification model (2.3), the likelihood of φ with full
response is
L =
n∏
i=1
[
pi(Xi,V 1i, Yi;φ)
Ri{1− pi(Xi,V 1i, Yi;φ)}1−Ri
]
, (2.7)
and under some regularity conditions, the maximum likelihood estimator (MLE)
of φ can be obtained by solving the score equation
S(φ) =
n∑
i=1
{Ri − pi(Xi, V1i, Yi;φ)}∂logit(pii)
∂φ
≡
n∑
i=1
s(Xi, Ri,V 1i, Yi;φ) = 0, (2.8)
where logit(pii) = log(pii/(1− pii)). Since some Yi are missing, the score function
(2.8) is not applicable. Alternatively, the MLE of φ can be obtained by solving
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the mean score equation
S¯(φ) ≡
n∑
i=1
E{s(X,R,V 1, Y ;φ)|Oi}
=
n∑
i=1
[Ris(Xi, 1,V 1i, Yi;φ) + (1−Ri)E0{s(Xi, 0,V 1i, Y ;φ)|Xi,V i}]
= 0, (2.9)
where E0(·|Xi,V i) = E(·|Xi,V i, Ri = 0) and
Oi =
{
(Xi, Ri,V i, Yi) if Ri = 1,
(Xi, Ri,V i) otherwise.
Using the mean score equation for estimating the MLE has been discussed by,
for example, Louis (1982), and Riddles, Kim and Im (2016).
We need to estimate the conditional distribution of unobserved Y given the
marker X and covariant V , or equivalently, the second term in (2.9). A simple
choice applies a parametrical disease model for all samples, as in Liu and Zhou
(2010). Instead of using a full parametric model, we consider an approach based
on the Bayes formula
Pr(Yi = 1|Xi,V i, Ri = 0) = Pr(Yi = 1|Xi,V i, Ri = 1)O(1, Xi,V i)∑1
y=0 Pr(Yi = y|Xi,V i, Ri = 1)O(y,Xi,V i)
, (2.10)
where
O(Y,X,V ) =
Pr(Ri = 0 | Y,X,V )
Pr(Ri = 1 | Y,X,V ) =
1− pi(X,V 1, Y ;φ)
pi(X,V 1, Y ;φ)
.
Thus, in addition to the verification model (2.3), we only need a model for ver-
ified samples Pr(Yi|Xi,V i, Ri = 1). Rotnitzky, Faraggi and Schisterman (2006)
also considered (2.10), but did not discuss the estimation of the nonignorability
parameter β. Kim and Yu (2011) used (2.10) to obtain a semiparametric es-
timation of the population mean under nonignorable nonresponse, assuming a
followup sample.
Here we specify a parametric model for Pr(Yi = y|Xi,V i, Ri = 1) and derive
Pr(Yi = y|Xi,V i, Ri = 0) based on (2.10). Let Pr(Yi = y|Xi,V i, Ri = 1) ≡
P1(y,Xi,V i;µ), where P1(·) is a known function and µ is an unknown parameter,
and write Pr(Yi = y|Xi,V i, Ri = 0) ≡ P0(y,Xi,V i;µ, φ), y = 1, 0. Using (2.10),
the conditional distribution of the unobserved Y reduces to
Pr(Yi = 1|Xi,V i, Ri = 0) = P1(1, Xi,V i;µ)e
β
1− P1(1, Xi,V i;µ)(1− eβ)
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≡ P0(1, Xi,V i;φ, µ).
Here, µ0 can be simply estimated by solving
S1(µ) =
n∑
i=1
Ri
[
Yi
∂log{P1(Yi, Xi,V i;µ)}
∂µ
+ (1− Yi)∂log{P1(1− Yi, Xi,V i;µ)}
∂µ
]
≡
n∑
i=1
Ris1(Xi,V i, Yi;µ) = 0. (2.11)
Thus, µ is estimated by maximizing the likelihood among the respondents. Once
we get a ML estimator µˆ from (2.11), we plug µˆ into (2.9) to solve for φ. We
write (2.9) as
S2(φ, µ)=
n∑
i=1
Ris(Xi,1,V1i,Yi;φ)+(1−Ri)
1∑
y=0
s(Xi,0,V1i,y;φ)P0(y,Xi,V i;φ, µ)
=
n∑
i=1
s2(Xi, Ri,Vi, Yi;φ, µ) = 0, (2.12)
where P0(0, Xi,V i;φ, µ) = 1− P0(1, Xi,V i;φ, µ).
The computation of φˆ from (2.12) can be implemented by an EM algorithm.
1. Specify the initial value φˆ(0).
2. For each t = 0, 1, 2, . . . , let φˆ(t+1) be the solution of
n∑
i=1
Ris(Xi, 1,V 1i, Yi;φ) + (1−Ri)
1∑
y=0
w
(t)
iy s(Xi, 0,V 1i, y;φ)
 = 0,
where w
(t)
iy = P0(y,Xi,V i; φˆ
(t), µˆ).
3. Set t = t+ 1 and go to step (2) until ||φˆ(t+1)− φˆ(t)||1 < , where  is a small
arbitrary number, say  = 10−5.
3. Asymptotic Properties
In this section, we establish some asymptotic properties of the proposed
propensity-score-adjustment AUC estimator Aˆiv. The regularity conditions and
the proofs are shown in the Supplementary Material.
Let
Dij(A, φ) = Ripi
−1
i (φ)Rjpi
−1
j (φ)Yi(1− Yj)(Iij −A),
and let A0 be the true AUC.
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Theorem 1. Suppose the regularity conditions (r1-r10) given in the Supplemen-
tary Material hold. We have
√
n(Aˆiv −A0) d→ N(0, σ2), (3.1)
where σ2 = V ar(Qi)/{Pr(Y = 0) Pr(Y = 1)}2, and
Qi = E(Dij +Dji|Oi)− Γ′E−1
{
∂s2(X,R, V, Y ;φ)
∂φ
}[
s2(Xi, Ri, Vi, Yi;φ, µ)
+E
{
s2(X,R,V , Y ;φ, µ)
∂µ
}
E−1
{
∂s1(X,V , Y ;µ)
∂µ
}
Ris1(Xi,V i, Yi;µ)
]
,
(3.2)
where Γ = ∂E(Dij)/∂φ and s2(·) were defined in (2.12).
A sketched proof of Theorem 1 is given in the Supplementary Material.
Pr(Y = 1), Pr(Y = 0) and V ar(Qi) can be consistently estimated by
∑n
i=1Ripˆi
−1
i
Yi/n,
∑n
i=1Ripˆi
−1
i (1−Yi)/n and ˆV ar(Qi) =
∑n
i=1(Qˆi−Q¯n)2/(n−1), respectively,
with
Qˆi =
n∑
j=1
{Dij(Aˆiv, φˆ) +Dji(Aˆiv, φˆ)}
n
− Γˆ′kEˆ−1
{
∂s2(X,R, V, Y ; φˆ, µˆ)
∂φ
}[
s2(Xi, Ri, Vi, Yi; φˆ, µˆ)
+ Eˆ
{
∂s2(x,R,V , Y ; φˆ, µˆ)
∂µ
}
Eˆ−1
{
∂s1(X,V , Y ; µˆ)
∂µ
}
Ris1(Xi,V i, Yi; µˆ)
]
,
Q¯n =
n∑
i=1
Qˆi
n
,
Eˆ−1
{
∂s2(X,R, V, Y ; φˆ, µˆ)
∂φ
}
= n
{
n∑
i=1
∂s2(Xi, Ri, Vi, Yi; φˆ, µˆ)
∂φ
}−1
,
Eˆ−1
{
∂s1(X,V, Y ; µˆ)
∂µ
}
= n
{
n∑
i=1
∂s1(Xi, Vi, Yi; µˆ)
∂µ
}−1
,
Eˆ
{
∂s2(X,R, V, Y ; φˆ, µˆ)
∂µ
}
=
n∑
i=1
n−1∂s2(Xi, Ri, Vi, Yi; φˆ, µˆ)
∂µ
,
and Γˆ = n−2
n∑
i=1
n∑
j=1
∂Dij
∂φ
.
Remark 1. To better understand the asymptotic variances in (3.1), we can
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further decompose V ar(Qi) in (3.2). Denote the first and second terms of the
right side of (3.2) as Qi1 and Qi2, respectively, so that Qi = Qi1 +Qi2. Rewrite
(3.2) as
V ar(Qi) = V ar(Qi1) + V ar(Qi2) + 2Cov(Qi1, Qi2).
Here,
V ar(Qi1) = V ar(Aˆf ){Pr(Y = 0) Pr(Y = 1)}2+E{g2(Xi, Yi,V i)(pi−1i −1)}, (3.3)
V ar(Qi2) = Γ
′T−122 Γ, (3.4)
Cov(Qi1, Qi2) = Γ
′T−122 E[(Dij +Dji){s2i + T21T−111 Ris1i}]
= 2Γ′T−122 Cov(Dij , s2i + T21T
−1
11 Ris1i), (3.5)
where Aˆf is the AUC estimator defined in (2.2) when there are no missing data,
g(Xi, Yi,V i) = Yi Pr(Y = 0){F0(Xi)−A0}+(1−Yi) Pr(Y = 1){1−F1(Xi)−A0},
with F0(·) and F1(·) the cumulative distribution function of X conditional on
Y = 0 and Y = 1, respectively. The derivation of variance decomposition (3.3)
and (3.5) are also given in the supplementary document.
In summary, the asymptotic variance of the proposed estimators can be
decomposed as
V ar(Qi) = V ar(Aˆf ){Pr(Y = 0) Pr(Y = 1)}2 + E{g2(Yi, Xi,V i)(pi−1i − 1)}
+ Γ′T−122 {Γ + 4Cov(Dij , s2i + T21T−111 Ris1i)}. (3.6)
The first term is the variance of Aˆf , where no missing data is assumed; the
second is due to the fact only partial samples are verified, pii < 1; the third term
Γ′T−122 Γ is the variance generated from estimating φ—the unknown parameter in
the verification model pi(·) and the connection between the statistic of interest
(here AUC) and the likelihood of φ and µ. Observe that the second and third
terms are zero when no data are missing. These terms can be treated as variances
produced by the missing mechanism. Here g(Xi, Yi,V i) does not depend on Ri
and pii. Compared to the estimator Aˆf using the full data, the increased variance
of our estimators are due to the estimation of φ and partial verification; a smaller
verification probability leads to a larger variance.
4. Numerical Studies
4.1. Simulation studies
To test our theory, we generated synthetic data similarly as Liu and Zhou
(2010): first generated the marker X ∼ unif(−1, 1) and the covariate V un-
der different scenarios, and then generated the outcome variable Y through the
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disease model on the full sample,
Pr(Yi = 1|Xi, Vi) = 1
1 + exp(µ1 + µ2Xi + µ3Vi)
,
and generated the missing indicator R though
pii = Pr(Ri = 1|Xi, Vi, Yi) = 1
1 + exp(ψ1 + ψ2Xi + ψ3Vi + βYi)
.
Under the above setting, the disease model on verified samples we fitted, is
Pr(Yi = 1|Xi, Vi, Ri = 1) = 1
1 + U(Xi, Vi) exp(µ1 + µ2Xi + µ3Vi)
,
where U(Xi, Vi) = {1 + exp(ψ1 + ψ2Xi + ψ3Vi + β)}/{1 + exp(ψ1 + ψ2Xi +
ψ3Vi)}, which is not equal to 1 when missingness is nonignorable, so Pr(Yi =
1|Xi, Vi, Ri = 1) does not follow a logistic distribution. However, in our simu-
lations, the logistic form is always tapped because of its prevalence in practice.
In this sense, we at least weakly misspecified the disease model on the verified
sample for nonignorable cases.
We took six scenarios:
(I). V ∼ Bernoulli(0.5), (µ1, µ2, µ3) = (2,−2.5,−1), (ψ1, ψ2, ψ3) = (1.2,−1, 0)
and β = −1.5. We fitted the disease model on verified samples in a logistic
form with explanatory variables X and V , while the working verification
model was another logistic model with V as the IV. Under this setting,
the verification model was correctly specified, with Y and V being weakly
correlated (the correlation coefficient between them is 0.16).
(II). Similar to scenario I, but with (µ1, µ2, µ3) = (2,−2.5,−1), (ψ1, ψ2, ψ3) =
(2,−1,−1) and β = 0. Under this setting, the verification model was incor-
rectly specified since ψ3 6= 0, with the correlation coefficient 0.16 between
Y and V , and 0.19 between R and V .
(III). V ∼ N(0, 1), (µ1, µ2, µ3) = (2,−2.5,−1), (ψ1, ψ2, ψ3) = (1,−1, 0) and β =
−1.5. We fitted the model similarly as in Scenario I, except that the working
disease model as sign(V )|V |1/3 instead of V . Under this setting, the working
disease model was incorrectly specified, with Y and V being moderately
correlated (the correlation coefficient between them is 0.28).
(IV). V ∼ N(0, 1), (µ1, µ2, µ3) = (0.5,−2.5,−1.5), (ψ1, ψ2, ψ3) = (2,−1,−0.8)
and β = −2. We fitted the model similarly as in Scenario I. Under this
setting, the working verification model was incorrectly specified, with Y
and V being weakly correlated.
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(V). V ∼ N(0, 1), (µ1, µ2, µ3) = (0.5,−2.5,−1), (ψ1, ψ2, ψ3) = (2,−1, 0.8) and
β = −2. We fitted the model similarly as in Scenario I except that the work-
ing disease model as sign(V )|V |1/3 instead of V . Under this setting, both
the working disease model and the verification model were incorrectly spec-
ified, with Y and V being moderately correlated (the correlation coefficient
between them is 0.32).
(VI). We generated more covariates: V1 ∼ Bernoulli(0.5), V2 ∼ N(0, 1) and V3 ∼
unif(0, 1). (µ1, µ2, µ3, µ4, µ5)=(0.6,−1.5, 0.5,−0.5, 0.5), (ψ1, ψ2, ψ3, ψ4, ψ5)
= (1,−1, 0.5,−0.5, 0.5) and β = −2. We fitted the working verification
model using V3 as IV since it was less correlated with R than other covari-
ates.
Table 1 summarizes some design statistics for each scenario, including whether
the working models are correctly specified, verification proportion, disease preva-
lence and the true AUC.
We considered 200 and 2,000 samples for each scenario and generated 500
data sets for each case. Four additional estimators were compared to the proposed
estimator: Aˆig, Aˆf , Aˆv and Aˆfp, which stand for the AUC estimators using the
ignorable assumption (β = 0 and without using IV), using full data, using verified
data only and using a full parametric disease model (Liu and Zhou (2010)),
respectively. We calculated Aˆig and Aˆfp in the same way as Aˆiv, therefore, these
estimators differs in the estimation of parameters φ and/or µ.
The estimator Aˆf was treated as the gold standard. A summary of the
simulation results is presented in Table 2, where the bias (defined as the mean
difference with Aˆf ), standardized sample variance (Svar) and standardized mean
square error (SMSE) are displayed for the six estimators considered. In Table
2, SVar (SMSE) of an estimator is defined as its variance (MSE) divided by
the variance (MSE) of Aˆf , and SMSE is also known as relative efficiency. The
median value of the estimated asymptotic variances for the proposed estimators
are compared with the Monte Carlo sample variances in Table 3. The following
conclusions can be made from the simulation results.
1. When the verification model is correctly specified (Scenarios I and III), the
proposed Aˆiv estimator achieves the best or almost the best performance.
Specifically, for nonignorable cases, Aˆiv has the smallest bias and smallest
variance. Also, Aˆiv achieved a closer coverage probability to the nominal
level than Aˆv, Aˆig and Aˆfp.
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Table 1. Summary statistics for the simulation design. Notation: for working disease
model, W – weak misspecification, i.e., disease model is misspecified as having a logistic
form, IC – incorrect specification, not only disease model is misspecified as having a
logistic form but also the covariates effect misspecified, for working verification model,
C – correct specification, the selected instrument variable (IV) is indeed an IV, IC –
incorrect specification, indicates that the selected IV is not an IV, I – ignorable scenario,
and NI – nonignorable scenario.
Scenario I II III IV V VI
Working disease model W W IC W IC W
Working verification model C IC C IC IC IC
Ignorable/Nonignorable NI I NI NI NI NI
Verification proportion 0.33 0.21 0.37 0.30 0.30 0.33
Prevalence 0.26 0.26 0.21 0.42 0.42 0.29
AUC 0.81 0.81 0.79 0.79 0.79 0.71
2. Aˆiv is robust to the disease model (Scenario III). In the disease model, the
true covariate’s effect is cubic while we fit a linear covariate’s effect. Aˆiv is
superior to Aˆv, Aˆig and Aˆfp.
3. When the verification model is incorrectly specified (Scenarios II, IV, V and
VI), in the sense of bias or variance, Aˆiv does not always outperform other
estimators, but in the sense of MSE and coverage probability, it outperforms
others. Moreover, the proposed estimator generally has similar bias as Aˆfp
but is more efficient than Aˆfp.
4. Further extensive simulation is reported in the supplementary document,
including scenarios similar to Scenario III but with different verification
proportion and different disease prevalence. The proposed estimator Aˆiv is
superior in these studies too.
The asymptotic variance of Aˆiv is compared with its sample variance in Table
3. When the verification model is correct (scenario I and III), the asymptotic
variance is very close to the sample variance: When the verification model is in-
correctly specified, the asymptotic variance is slightly biased. This indicates that
the variance estimation is slightly sensitive to the specification of the verification
model.
4.2. Example
We used the Alzheimer’s Disease (AD) data set collected by the National
Alzheimer’s Coordinating Center (NACC) to illustrate the proposed method.
Liu and Zhou (2010) have analysed an earlier version of this data; the current
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Table 2. Monte Carlo bias, standardized variance (SVAR), standardized mean squared
error (SMSE) and 95% coverage probability (CP) of AUC estimators in simulation study.
Aˆf , Aˆiv, Aˆig, Aˆv and Aˆfp stand for the AUC estimators using full data, using IV method,
using ignorable assumption (missing at random), using verified data only and using a full
parametric disease model (Liu and Zhou (2010)), respectively. SVar and SMSE stand
for the standardized variance, and standardized MSE, respectively. SVar (SMSE) of an
estimator is defined as its variance (MSE) divided by the variance (MSE) of Aˆf . Note
that SMSE is also known as relative efficiency and CP for each AUC estimator was
calculated using the median of the sample estimators of the corresponding asymptotic
variances.
n = 200 n = 2,000
Scenario Estimators Bias SVar SMSE CP Bias SVar SMSE CP
Aˆf 0.000 1.000 1.000 0.95 0.000 1.000 1.000 0.95
Aˆiv −0.006 2.997 3.046 0.93 −0.009 3.167 3.973 0.92
I Aˆfp −0.064 11.949 15.276 0.74 −0.067 63.574 104.644 0.51
Aˆig −0.027 5.138 5.712 0.85 −0.018 4.132 6.997 0.80
Aˆv −0.062 3.449 6.615 0.80 −0.059 3.080 34.647 0.10
Aˆf 0.000 1.000 1.000 0.95 0.000 1.000 1.000 0.95
Aˆiv −0.003 4.551 4.557 0.92 −0.017 3.833 6.588 0.88
II Aˆfp −0.007 8.766 8.811 0.84 −0.010 14.601 15.585 0.82
Aˆig 0.006 5.748 5.776 0.91 0.001 5.773 5.778 0.91
Aˆv −0.029 4.632 5.293 0.89 −0.032 4.871 13.968 0.69
Aˆf 0.000 1.000 1.000 0.95 0.000 1.000 1.000 0.96
Aˆiv −0.004 2.307 2.317 0.95 −0.009 2.292 2.970 0.93
III Aˆfp −0.059 9.031 11.478 0.72 −0.058 45.982 71.221 0.80
Aˆig −0.015 3.589 3.757 0.88 −0.019 3.424 6.148 0.80
Aˆv −0.062 2.907 5.657 0.79 −0.063 2.525 31.856 0.10
Aˆf 0.000 1.000 0.95 1.000 0.000 1.000 1.00 0.95
Aˆiv 0.020 6.065 6.434 0.93 0.035 6.196 18.72 0.72
IV Aˆfp −0.038 11.557 12.972 0.82 −0.022 32.353 37.08 0.77
Aˆig −0.044 9.874 11.714 0.82 −0.040 8.482 24.95 0.63
Aˆv −0.055 5.837 8.788 0.86 −0.056 4.992 36.91 0.34
Aˆf 0.000 1.000 1.000 0.95 0.000 1.000 1.00 0.95
Aˆiv 0.016 6.520 6.760 0.91 0.034 7.604 19.44 0.70
V Aˆfp −0.034 11.368 12.486 0.83 −0.039 47.822 63.30 0.62
Aˆig −0.041 9.568 11.203 0.83 −0.037 7.928 22.08 0.67
Aˆv −0.055 5.837 8.788 0.86 −0.056 4.992 36.91 0.37
Aˆf 0.000 1.000 1.000 0.95 0.000 1.000 1.00 0.96
Aˆiv −0.049 5.109 6.756 0.89 −0.041 4.875 16.24 0.79
VI Aˆfp −0.049 6.659 8.313 0.83 −0.044 10.281 23.87 0.75
Aˆig −0.053 6.777 8.741 0.83 −0.044 5.807 18.93 0.82
Aˆv −0.079 3.712 8.070 0.83 −0.069 3.671 36.08 0.52
data includes the Uniform Data Set (UDS) data up through the September 2014
freeze. Here we want to study the diagnostic ability of the medical test Mini
Mental State Examination (MMSE) in detecting AD. MMSE ranges from 0 to
30, with lower scores corresponding to larger risks of having cognitive impairment.
The gold standard for AD is based on a primary neuropathological diagnostic test
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Table 3. Variance comparison. SV , AV stand for sample variance and the median of
estimated asymptotic variance for Aˆiv.
Scenario n 1,000× SV 1,000×AV
I 200 3.7 3.5
2,000 0.4 0.3
II 200 5.6 5.3
2,000 0.4 0.5
III 200 3.2 3.1
2,000 0.3 0.3
IV 200 6.2 5.0
2,000 0.6 0.6
V 200 6.7 5.0
2,000 0.7 0.6
VI 200 7.3 7.9
2,000 0.7 0.9
(NPTH), which requires brain autopsy. Some patients or their family do not wish
a brain autopsy. These are the main reasons for missing disease status, and only
about 10% patients have been verified. Originally, there were several values of
NPTH, for example, “Normal”, “definitely AD”, “probably AD”, “possible AD”,
etc; we define AD as “definitely AD” (Y = 1) and treat others as control sample
(Y = 0). Five covariants, AGE, SEX, marriage status (MRGS), Depression
(DEP) and Parkinson’s disease (PD) were considered; these are known to be
related to AD or the disease verification. After removing missing values in MMSE
and covariants, 52,673 samples remain, in which 5,707 samples were verified by
autopsy. In the verified sample, 55% were AD. We also categorized MRGS into
two groups; coding “never married” as 1 and the others as 0. The boxplots for
MMSE are shown in Figure 1, which shows that lower MMSE scores are more
likely to be associated with AD.
We fitted a logistic regression model as the disease model for verified samples:
Pr(Yi = 1|Xi,V i, Ri = 1) = 1
1 + exp(µ1 + µ2Xi +µ′3V i)
, (4.1)
where V represents the vector of covariates (AGE, SEX, MRGS, PD, DEP), R
indicates whether X is observed, and Y and X stand for MMSE and true disease
status, respectively. The verification model is the logistic regression model
pii = Pr(Ri = 1|Xi,V i, Yi) = 1
1 + exp(ψ1 + ψ2Xi +ψ ′3V 1i + βYi)
, (4.2)
where V1 are the covariates without the selected IV. For demonstration purposes,
we simply select AGE as the instrument variable, so V 1 stands for the reduced
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Table 4. Coefficients, Standard error (SE) and p-values.
Disease model Verification model
coefficient SE P-value coefficient SE P-value
Intercept 1.068 0.244 < 0.001 2.358 0.222 < 0.001
MMSE (X) −0.079 0.003 < 0.001 0.043 0.008 < 0.001
MRGS −0.125 0.068 0.065 0.203 0.054 < 0.001
PD −0.994 0.107 < 0.001 −0.994 0.107 < 0.001
SEX −0.309 0.064 < 0.001 −0.755 0.036 < 0.001
AGE 0.005 0.003 0.085 —
DEP −0.076 0.086 0.375 0.195 0.053 < 0.001
AD (Y) — −3.777 2.306 0.104
covariate vector (MRGS, SEX, PD, DEP). In the Supplementary Material, we
extend our study by using different variables as IV. Most of the studies lead to
nonsignificant β or non-convergence, which indicates that there may be no good
IV in practice.
The estimated parameters, standard errors and their p-values are listed in
Table 4; the p-value was decided by a Wald-statistic and the asymptotic vari-
ances calculated according to Lemma 1.1 in the Supplementary Material. All
parameters except DEP in the diseased model are significant. The nonignorable
parameter β is estimated to be −3.777 (two-side p-value is about 0.10), which in-
dicates that the missing mechanism may be nonignorable. β = −3.777 indicates
that the odds of verification for diseased individuals is about exp(3.78)
.
= 43
units larger than it for non-diseased individuals with the same values of (MRGS,
SEX, PD, DEP).
The AUC value calculated using only verified samples is 0.699 (95% Con-
fidence Interval (CI): 0.686, 0.713), and the proposed estimators Aˆiv = 0.786
(95% CI: 0.754, 0.818). The 95% CIs were constructed using the normal distri-
bution. There is a significant difference between our AUC estimators and the
AUC calculated only using verified samples (Wald test, p-value < 0.001). The
full parametric model in this example is not convergent and, based on our study,
using AGE as IV is just for an illustrative example, there may not be good choices
of IV here.
5. Concluding Remarks
As it is hard to specify a verification model correctly, sensitivity analyses,
as suggested by Rotnitzky, Faraggi and Schisterman (2006), can be used to com-
plement the non-robustness. One could also consider nonparametric techniques
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Figure 1. Boxplots for MMSE. “All” – using all samples, “Verified” – using all verified
samples, “AD” – using verified AD samples, and “AD-free” – using verified AD-free
samples.
such as kernel regression models for the disease model. Bayesian modeling cou-
pled with sensitivity analyses in the context of missing data (Daniels and Hogan
(2008)) can also be considered for further analyses. This can be a topic of future
study.
The proposed method is based on the instrumental variable (IV) assump-
tion. We used the variable that had the lowest marginal correlation with R (the
verification status) as the IV in our simulation study, which led to good per-
formance. This method is not ideal but is simple. Selecting IV is not easy. A
good practicable example of IV choice was introduced by Wang, Shao and Kim
(2014) for a study of a data set from the Korean Labor and Income Panel Survey
(KLIPS). We need more future studies on choosing IV.
After estimating the verification probability and disease probability for each
individual, other types of AUC estimators can be used, for example, the other
AUC estimators introduced in Alonzo and Pepe (2005) or Liu and Zhou (2010),
such as using full imputation (FI) method or mean score imputation (MSI)
method instead of inverse probability weighting (IPW) method. The proposed
Instrumental Variable method can also be used for FL and MSI. Liu and Zhou
(2010) noticed that FI and MSI method generally performed better than the IPW
method. One probable reason is that for the IPW method, there are 1/pˆii terms,
2164 YU, KIM AND PARK
and this may produce extreme values for the AUC estimator and its correspond-
ing asymptotic variance estimator if the pˆii are small. In addition to AUC, the
proposed method can be easily extended to the estimation of the other indexes
related to ROC curve, such as sensitivity, specificity, and the partial area under
the curve (McClish (1989)) as well as the modified area under the Curve (Yu,
Chang and Park (2014)).
Supplementary Materials
Supplementary material is available online at http://www3.stat.sinica.edu.
tw/statistica/, including proofs of Theorem 3.1, (3.3) and (3.5), and the results
from extra numeric studies. The source codes for some of the simulation studies
are available on https://github.com/wbaopaul/AUC-IV.
Acknowledgment
The research of Jae Kwang Kim was partially supported by Brain Pool pro-
gram (131S-1-3-0476) from the Korean Federation of Science and Technology So-
ciety and by a grant from NSF (MMS-1733572). The work of Taesung Park was
supported by the Bio & Medical Technology Development Program of the NRF
grant (2013M3A9C4078158) and by grants of the Korea Health Technology R &
D Project through the Korea Health Industry Development Institute (KHIDI),
funded by the Ministry of Health & Welfare, Republic of Korea (HI16C2037,
HI15C2165). The NACC database is funded by NIA/NIH Grant U01 AG016976.
NACC data are contributed by NIA funded ADCs.
References
Alonzo, T. A. and Pepe, M. S. (2005). Assessing accuracy of a continuous screening test in the
presence of verification bias. Journal of the Royal Statistical Society C (Applied Statistics)
54, 173–190.
Baker, S. G. (1995). Evaluating multiple diagnostic tests with partial verification. Biometrics
51, 330–337.
Bamber, D. (1975). The area above the ordinal dominance graph and the area below the receiver
operating characteristic graph. Journal of Mathematical Psychology 12(4), 387–415.
Begg, C. B. and Greenes, R. A. (1983). Assessment of diagnostic tests when disease verification
is subject to selection bias. Biometrics 39, 207–215.
Daniels, M. J. and Hogan, J. W. (2008). Missing Data in Longitudinal Studies: Strategies for
Bayesian Modeling and Sensitivity Analysis. Chapman & Hall / CRC.
He, H., Lyness, J. M. and McDermott, M. P. (2009). Direct estimation of the area under the
AUC ESTIMATION UNDER NONIGNORABLE VERIFICATION BIAS 2165
receiver operating characteristic curve in the presence of verification bias. Statistics in
Medicine 28(3), 361–376.
He, H. and McDermott, M. P. (2011). A robust method using propensity score stratification for
correcting verification bias for binary tests. Biostatistics 0, 1–15.
Kim, J. K. and Yu, C. L. (2011). A semi-parametric estimation of mean functionals with non-
ignorable missing data. Journal of the American Statistical Association 106, 157–165.
Kosinski, A. S. and Barnhart, H. X. (2003). Accounting for nonignorable verification bias in
assessment of diagnostic tests. Biometrics 59(1), 163–171.
Liu, D. and Zhou, X.-H. (2010). A model for adjusting for nonignorable verification bias in
estimation of the ROC curve and its area with likelihood-based approach. Biometrics
66(4), 1119–1128.
Louis, T. A. (1982). Finding the observed information matrix when using the EM algorithm.
Journal of the Royal Statistical Society. Series B (Statistical Methodological) 44, 226–233.
McClish, D. K. (1989). Analyzing a portion of the ROC curve. Medical Decision Making 9(3),
190–195.
Riddles, M. K., Kim, J. K. and Im, J. (2016). Propensity-score-adjustment method for nonig-
norable nonresponse. Journal of Survey Statistics and Methodology 4(2), 215–245.
Rodenberg, C. and Zhou, X.-H. (2000). ROC curve estimation when covariates affect the veri-
fication process. Biometrics 56(4), 1256–1262.
Sverchkov, M. (2008). A new approach to estimation of response probabilities when missing
data are not missing at random. Proceeding of the Section on Survey Research Methods,
867-874.
Rotnitzky, A., Faraggi, D. and Schisterman, E. (2006). Doubly robust estimation of the area
under the receiver-operating characteristic curve in the presence of verification bias. Journal
of the American Statistical Association 101(475), 1276–1288.
Wang, S., Shao, J. and Kim, J. K. (2014). An instrumental variable approach for identification
and estimation with nonignorable nonresponse. Statistic Sinica 24, 1097–1116.
Yu, W., Chang, Y. I. and Park, E. (2014). A modified area under the ROC curve and its
application to marker selection and classification. Journal of the Korean Statistical Society
43(2), 161–175.
Zhou, X.-H. (1996). A nonparametric maximum likelihood estimator for the receiver operating
characteristic curve area in the presence of verification bias. Biometrics 52, 299–305.
Zhou, X.-H. (1998). Comparing correlated areas under the ROC curves of two diagnostic tests
in the presence of verification bias. Biometrics 54, 453–470.
Zhou, X.-H. and Castelluccio, P. (2003). Nonparametric analysis for the ROC areas of two
diagnostic tests in the presence of nonignorable verification bias. Journal of Statistical
Planning and Inference 115(1), 193–213.
Zhou, X.-H. and Castelluccio, P. (2004). Adjusting for non-ignorable verification bias in clinical
studies for alzheimer’s disease. Statistics in Medicine 23(2), 221–230.
Zhou, X.-H., Obuchowski, N. A. and McClish, D. K. (2011). Statistical Methods in Diagnostic
Medicine, Volume 712. John Wiley & Sons.
Zhou, X.-H. and Rodenberg, C. A. (1998). Estimating an ROC curve in the presence of non-
ignorable verification bias. Communications in Statistics-Theory and Methods 27(3), 635–
657.
2166 YU, KIM AND PARK
Department of Biomedical and Health Informatics, Division of Oncology and Center for Child-
hood Cancer Research, Childrens Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
E-mail: wbaopaul@gmail.com
Department of Statistics, Iowa State University, Ames, IA 50011, USA.
E-mail: jkim@iastate.edul
Department of Statistics, Seoul National University, Shilim-Dong, Kwanak-Gu, Seoul 151-742,
Korea.
E-mail: taesungp@gmail.com
(Received June 2016; accepted December 2017)
